Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine.
Cheryl KeechGary AlbertIksung ChoAndreana RobertsonPatricia ReedSusan NealJoyce S PlestedMingzhu ZhuShane Cloney-ClarkHaixia ZhouGale SmithNita PatelMatthew B FriemanRobert E HauptJames P LogueMarisa McGrathStuart WestonPedro A PiedraChinar DesaiKathleen CallahanMaggie LewisPatricia Price-AbbottNeil FormicaVivek ShindeLouis FriesJason D LickliterPaul GriffinBethanie WilkinsonGregory M GlennPublished in: The New England journal of medicine (2020)
At 35 days, NVX-CoV2373 appeared to be safe, and it elicited immune responses that exceeded levels in Covid-19 convalescent serum. The Matrix-M1 adjuvant induced CD4+ T-cell responses that were biased toward a Th1 phenotype. (Funded by the Coalition for Epidemic Preparedness Innovations; ClinicalTrials.gov number, NCT04368988).